Perspective Therapeutics sells brachytherapy business to GT Medical

Perspective Therapeutics, Inc.

Transaction expected to close Q1 2024; assets include Cesium-131 seed IP, equipment, Richland, WA lease.
Consideration: 0.5% equity in GT Medical plus tiered cash royalties over 4 years (3-5% on seed sales, 0.5% on GammaTile).
Company retains most liabilities (environmental, warranty, taxes, accounts payable) and all accounts receivable.
Sale aligns resources with lead-based alpha-particle therapy pipeline (melanoma VMT01, neuroendocrine VMT-α-NET).
GT Medical gains control of Cesium-131 seed production, expanding its GammaTile Therapy customer base.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into Asset Purchase Agreement with GT Medical Technologies, Inc. (effective 2023-12-07).

Action: entry
Agreement: asset purchase
Counterparty: GT Medical Technologies, Inc.
Effective: 2023-12-07

Exact text from the filing

On December 7, 2023, Isoray Medical, Inc. (“ Medical ”), a Delaware corporation and wholly-owned subsidiary of Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) by and among Medical, the Company, and GT Medical Technologies, Inc., a Delaware corporation (“ GT Medical ”).

View on SEC.gov

230 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-034134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.